Abstract
Background Children undergoing hematopoietic stem cell transplantation (HCT) are at high risk of acquiring antibiotic-resistant bacteria. Few prior studies examined antibiotic resistance genes (ARGs) within the gut metagenomes of children undergoing HCT.
Methods We conducted a longitudinal study of children (age <18 years) undergoing HCT at a single institution. We performed shotgun metagenomic sequencing of fecal samples collected between days -30 and +100 relative to HCT. We evaluated the effects of aerobic (cefepime, vancomycin, fluoroquinolones, aminoglycosides, macrolides, and trimethoprim-sulfamethoxazole) and anaerobic (piperacillin-tazobactam, carbapenems, metronidazole, and clindamycin) antibiotic exposures on the diversity and composition of the gut microbiome and resistome.
Findings Using metagenomic data from 693 fecal samples collected from 80 children, we identified 350 unique ARGs. The most frequent ARGs identified encode resistance to tetracycline (n=91), beta-lactams (n=80), and fluoroquinolones (n=76). Both aerobic and anaerobic antibiotic exposures were associated with a decrease in the number of bacterial species (aerobic, β=0.72, 95% CI: 0.66, 0.79; anaerobic, β=0.68, 95% CI: 0.61, 0.76) and the number of unique ARGs (aerobic, β=0.83, 95% CI: 0.76, 0.91; anaerobic, β=0.84, 95% CI: 0.76, 0.93) within the gut metagenome. However, only anaerobic antibiotics were associated with an increase in the number of newly acquired ARGs (29%, 95% CI: 10%, 52%) and the abundance of ARGs (95%, 95% CI: 59%, 138%) in the gut resistome. Specific antibiotic exposures were associated with distinct changes in the number and abundance of resistance genes for individual antibiotic classes.
Interpretation The gut metagenome and resistome of children are highly dynamic throughout HCT, driven largely by antibiotic exposures. Compared to antibiotics without anaerobic activity, anaerobic antibiotics were associated with increased microbiome instability and expansion of the gut resistome.
Funding Antibacterial Resistance Leadership Group, National Institutes of Health, Duke Children’s Health & Discovery Initiative, Children’s Miracle Network Hospitals
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Research reported in this publication was supported in part by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under Award Number UM1AI104681. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. This work was additionally supported by the National Institute of Child Health and Human Development of the National Institutes of Health [T32HD094671 to S.M.H.], the National Human Genome Research Institute of the National Institutes of Health [T32 HG008955 to S.M.H.], the Translating Duke Health Ending Disease Where it Begins Working Group [to S.M.H.], the local efforts of the Duke Childrens Office of Development and its Childrens Miracle Network Hospitals fundraising corporate partnerships and programs [to S.M.H.], and a National Institutes of Health Career Development Award [K23-AI135090 to M.S.K.].
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
We obtained informed consent from participants legal guardians prior to enrollment, and the study protocol was approved by the Duke University Health System Institutional Review Board.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data not included in the manuscript will be available by request to the corresponding authors. All metagenomic data will be uploaded to the Sequence Read Archive.
